Blueprint Medicines Corporation

This study continues monitoring the safety of avapritinib for people with systemic mastocytosis who previously participated in related trials and are still benefiting from the medication. It tracks side effects and safety issues over a longer period. The goal is to better underst…

This study is testing whether adding the experimental drug BLU-263 (elenestinib) to standard symptom treatments helps people with indolent systemic mastocytosis better control their symptoms. Researchers will compare BLU-263 against a placebo in over 500 participants whose sympto…

This study is testing an investigational oral drug called BLU-808 for people with chronic hives that are not well-controlled by standard allergy medicines. The main goals are to see if the drug is safe and if it can reduce hive symptoms and flare-ups. The trial will enroll about …

This study is observing how well the medication avapritinib works for people with indolent systemic mastocytosis (ISM) in real-life medical settings. It will follow about 80 participants in Germany for up to two years, focusing on whether the drug improves their quality of life a…

This early-stage study aims to understand how a new drug called elenestinib might change how the body processes two common medications: a sedative (midazolam) and a birth control pill. Researchers will give these medications to 20 healthy adult women, both with and without elenes…

This study aims to find out how often a specific genetic change (the KIT D816V mutation) is present in people who have symptoms that suggest a type of mast cell disease. Researchers will enroll about 450 participants who have unexplained severe allergic reactions, certain chronic…